Peer-influenced content. Sources you trust. No registration required. This is HCN.
British Medical Journal
Explore this extensive study that highlights the recent major advancements in the prognosis for women with early invasive breast cancer while also emphasizing the impact of personal factors on mortality risk.
Oncology, Medical June 27th 2023
ACP Internist
Despite the demonstrated benefits of the recommended quadruple therapy for heart failure, its cost-effectiveness is highly sensitive to drug pricing, necessitating more thorough scrutiny and potential policy interventions to ensure equitable patient access.
Cardiology June 22nd 2023
OBR Oncology
A deeper understanding of the impact of smoking and vaping on cancer survivor symptom burdens might open new avenues for tailoring smoking cessation interventions. Uncover how these findings could challenge common assumptions and transform symptom management strategies in our recent article.
Cardiology June 20th 2023
MDLinx
Promising Discovery: Existing Drugs Could Be Repurposed for First Treatment of Dementia-Linked Strokes Clinical trials reveal the potential of two commonly used cardiac drugs, isosorbide mononitrate and cilostazol, to serve as novel treatment options for lacunar strokes, a leading cause of dementia. Key Points: “Now we understand more about what is triggering these small vessel strokes to attack the brain, we’ve been able to focus our efforts on treatments that can put a halt to this damage…as these drugs are already widely available for other circulatory disorders, and inexpensive, it shouldn’t take too long to move our findings from research into everyday clinical practice.” Professor Joanna Wardlaw of the University of Edinburgh and UK Dementia Research Institute
Cardiology June 13th 2023
The New England Journal of Medicine
Pembrolizumab Enhances Outcomes in Early-Stage NSCLC: A Phase 3 Trial Analysis In the pursuit of improved treatment outcomes for early-stage non-small-cell lung cancer (NSCLC), a phase 3 trial evaluated the efficacy of perioperative pembrolizumab. “Among patients with resectable, early-stage NSCLC, neoadjuvant pembrolizumab plus chemotherapy followed by resection and adjuvant pembrolizumab significantly improved event-free survival, major pathological response, and pathological complete response as compared with neoadjuvant chemotherapy alone followed by surgery.” Study Conclusions, KEYNOTE-671 ClinicalTrials.gov number, NCT03425643
Oncology, Medical June 12th 2023
Annals of Internal Medicine
Similarities in Quality and Cost of Care: Allopathic vs. Osteopathic Physicians As the medical field continues to evolve and diversify, it is imperative to understand the impact of physician education on patient outcomes and healthcare costs. This comprehensive observational study offers an insightful comparison between allopathic and osteopathic physicians in the context of hospitalized Medicare patients, revealing striking similarities in both the quality and cost of care provided.
Family Medicine/General Practice June 6th 2023